• Celldex released Phase 2 topline data for barzolvolimab in prurigo nodularis; the study missed the primary endpoint at Week 12.
• Key secondary endpoints also missed; results did not separate from placebo on itch or lesion measures through Week 24.
• Celldex discontinued the Phase 2 prurigo nodularis program; safety was consistent with prior studies despite marked serum tryptase reductions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.